• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Adderall (mixed salts of a single-entity amphetamine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Adderall (mixed salts of a single-entity amphetamine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Adderall has been indicated for use in children three years of age and older with ADHD as an integral part of a total treatment program which typically includes psychological, educational, and social measures.

    Adderall may improve attention span, decrease distractibility, and increase the ability to follow directions and finish tasks. The therapy may also improve the subject's ability to think before acting (decrease impulsivity), decrease hyperactivity and improve legibility of handwriting. In addition, aggression may decrease in youngsters with ADHD.

    Adderall is available in 10 mg and 20 mg double-scored tablets.

    Side Effects

    Adderall is generally well tolerated with few adverse reactions reported. The most frequently reported adverse reactions include anorexia, insomnia, stomach pain, headache, irritability, and weight loss. As with most psychostimulants indicated for ADHD, the possibility of growth suppression and the potential for precipitating motor tics and Tourette Syndrome exists with Adderall treatment, and in rare cases exacerbations of psychosis have been reported. Since psychostimulants have a high potential for abuse, Adderall should only be prescribed as part of an overall treatment program for ADHD with close physician supervision.

    Additional Information

    Adderall had previously been approved and marketed by another company under the name of Obetrol, indicated for exogenous obesity and ADHD. Richwood acquired the company, including the formulation and manufacturing rights to Obetrol, and renamed the product Adderall in 1994.

    Company Name: Richwood Pharmaceutical
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing